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Autism and autism spectrum disorders (ASDs) are heterogeneous neurodevelopmental disorders. They are enigmatic conditions
that have their origins in the interaction of genes and environmental factors. ASDs are characterized by dysfunctions in social
interaction and communication skills, in addition to repetitive and stereotypic verbal and nonverbal behaviours. Immune
dysfunction has been conﬁrmed with autistic children. There are no deﬁned mechanisms of pathogenesis or curative therapy
presently available. Indeed, ASDs are still untreatable. Available treatments for autism can be divided into behavioural, nutritional,
and medical approaches, although no deﬁned standard approach exists. Nowadays, stem cell therapy represents the great promise
for the future of molecular medicine. Among the stem cell population, mesenchymal stem cells (MSCs) show probably best
potentialgoodresultsinmedicalresearch.DuetotheparticularimmuneandneuraldysregulationobservedinASDs,mesenchymal
stem cell transplantation could oﬀer a unique tool to provide better resolution for this disease.
1.AutismSpectrumDisorders
Autism and autism spectrum disorders (ASDs) are heteroge-
neousneurodevelopmentaldisorders[1].Theyareenigmatic
conditions that have their origins in the interaction of
genes and environmental factors. ASDs are characterized by
dysfunctions in social interaction and communication skills,
inadditiontorepetitiveandstereotypicverbalandnonverbal
behaviours [2, 3]. Several biochemical events are associ-
ated with ASDs: oxidative stress; endoplasmic reticulum
stress; decreased methylation capacity; limited production
of glutathione; mitochondrial dysfunction; intestinal dysbio-
sis; increased toxic metal burden; immune dysregulation;
immuneactivationofneuroglialcells[4].Theexactaetiology
of ASDs is unknown, likely it results from a complex combi-
nationofgenetic,environmental,andimmunologicalfactors
[5, 6]. This heritable disorder derives from genetic variations
in multiple genes [7], making its treatment particularly
diﬃcult. Environment (i.e., air pollution, organophosphates,
and heavy metals) also contributes to the incidence of ASDs
[8].
Frequency of these disorders is increasing: 56% reported
increase in paediatric prevalence between 1991 and 1997
[9] until present rates of about 60 cases per 10,000 chil-
dren, according to Center for Disease Control [10, 11].
ASDs are increasingly being recognized as a public health
problem [12]. Pathophysiology and deﬁned mechanisms of
pathogenesis of autism remain still unclear. There are no2 Journal of Biomedicine and Biotechnology
drugs eﬀective for treatment of core symptoms of ASDs
[10]. Indeed, ASDs are still untreatable. Current available
treatments for autism can be divided into behavioural,
nutritional, and pharmacological options, in addition to
individual and family psychotherapy and other nonphar-
macologic interventions [13]. However, no deﬁned stan-
dard approach exists [14]. Pharmacological approaches are
direct towards neuropsychiatric disorders coassociated with
ASDs. Psycho-stimulants, alpha-2 agonists, beta blockers,
lithium, anticonvulsant mood stabilizers, atypical antipsy-
chotics, traditional antipsychotics, selective serotonin reup-
take inhibitors, antidepressants, and antipsychotics, are
drugs commonly prescribed [14–16]. Catatonia is treated
with lorazepam and bilateral electroconvulsive therapy [17].
Selective serotonin reuptake inhibitors are prescribed for the
treatment of depression, anxiety, and obsessive-compulsive
ASD-associated behaviours [2].
Other nonpsychotropic drugs which are supported by
at least 1 or 2 prospective randomized controlled trials or
1 systematic review include melatonin, acetylcholinesterase
inhibitors, naltrexone, carnitine, tetrahydrobiopterin, vita-
min C, hyperbaric oxygen treatment, immunomodulation
andanti-inﬂammatorytreatments,oxytocin,andevenmusic
therapy and vision therapy [18].
Alternative and complementary treatments, not suﬃ-
ciently supported by medical literature, include herbal reme-
dies, vitamin and mineral therapies, piracetam, elimina-
tion diets, chelation, cyproheptadine, famotidine, glutamate
antagonists, special dietary supplements, acupuncture, neu-
rofeedback, and sensory integration training [14, 19, 20]. On
the other hand, behavioural treatment could represent the
eﬀective intervention strategy for autism [21–23]. A plethora
of behavioural strategies and social skill trainings have been
used [24–26]. However, it has been demonstrated that no
deﬁnitive behavioural intervention completely improves all
symptoms for all ASD patients [27, 28].
Summarizing, all these therapies indicate that further
research is needed to better address treatment of several
medical conditions experienced by ASD patients [29].
2.Mesenchymal StemCells
Nowadays, stem cell therapy represents the great promise
for the future of molecular medicine. The progression of
several diseases can be slowed or even blocked by stem cell
transplantation [30].
Among the stem cell population, mesenchymal stem cells
(MSCs) show probably best potential good results in medical
research[31–33].Thesecellsarenonhematopoieticstemcells
having a multilineage potential, as they have the capacity of
diﬀerentiatingintobothmesenchymalandnonmesenchymal
lineages. MSCs are a population of progenitor cells of meso-
dermal origin found principally in the bone marrow of
adults,giving rise to skeletal muscle cells,blood, fat,vascular,
andurogenitalsystems,andtoconnectivetissues throughout
the body [34–36]. According to the International Society
of Cellular Therapy, MSCs are deﬁned by the following
minimal set of criteria: (1) grown in adherence to plastic
surface of dishes when maintained in standard culture
conditions; (2) express cytospeciﬁc cell surface markers, that
is, CD105, CD90, and CD73, to be negative for other cell
surface markers, that is, CD45, CD34, CD14, and CD11b;
(3) possess the capacity to diﬀerentiate into mesenchymal
lineages, under appropriate in vitro conditions [37]. MSCs
can be isolated from diﬀerent tissues other than bone
marrow: adipose tissue, liver, tendons, synovial membrane,
amniotic ﬂuid, placenta, umbilical cord, and teeth. MSCs
show a high expansion potential, genetic stability, stable
phenotype, high proliferation rate as adherent cells, and
self-renew capacity and can be easily collected and shipped
from the laboratory to the bedside and are compatible with
diﬀerent delivery methods and formulations [38, 39]. In
addition, MSCs have two other extraordinary properties:
they are able to migrate to sites of tissue injury, where they
are able to inhibit the release of proinﬂammatory cytokines
and have strong immunosuppressive activity that renders
them a useful tool for successful autologous, as well as
heterologous, transplantations without requiring pharma-
cological immunosuppression [40–43]. Besides, MSCs are
easily isolated from a small aspirate of bone marrow and
expanded with high eﬃciency [44]. Given that MSCs are
multipotent cells with a number of potential therapeutic
applications, and they represent a future powerful tool in
regenerative medicine, including ASDs. Mesenchymal stem
cells could be transplanted directly without genetic modiﬁ-
cation or pretreatments. They simply eventually diﬀerentiate
according to cues from the surrounding tissues and do
not give uncontrollable growth or tumours. In clinical
application, there is no problem with immune rejection
because of their in vivo immunosuppressive properties [45,
46]. In addition, MSCs can readily be isolated from the
patients requiring transplant or from their parents. There is
alsonotumourformationontransplantation[47].Nomoral
objection or ethical controversies are involved [48].
In principle, mesenchymal stem cells can act through
several possible mechanisms, that is, stimulating the plastic
response in the host damaged tissue, secreting survival-
promoting growth factors, restoring synaptic transmitter
release by providing local reinnervations, integrating into
existing neural and synaptic network, and reestablishing
functional aﬀerent and eﬀerent connections [49]. Since
MSCs have the capability to produce a large array of
trophic and growth factors both in vivo and in vitro. (MSCs
constitutively secrete interleukins (IL)-6, IL-7, IL-8, IL-11,
IL-12, IL-14, IL-15, macrophage colony-stimulating factor,
Flt-3 ligand, and stem-cell factor [50]). A more reasonable
explanation for the functional beneﬁt derived from MSC
transplantation is their paracrine activity, by which these
cells are able to produce factors that activate endogenous
restorative mechanisms within injured tissues contributing
to recovery of function lost as a result of lesions [49, 51].
3. Autism, Personalized Therapy through
Mesenchymal Stem Cells
MSCs have a strong long-lasting immunosuppressive capac-
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disorder (ASD) treatment. In humans, ASDs are associated with immune alterations and pro-inﬂammatory cytokines (i.e., IL-1β)o v e r -
production.Thesecytokinesareabletotriggerpro-inﬂammatorycellularevents.DatafrominvitromodelsshowthatMSCsareabletoaﬀect
not only T cells, but also other cells of the immune system (i.e., NK cells). Immunoregulatory properties of MSCs are through secretion
of large amounts of several bioactive molecules (paracrine activity), that is, PGE-2, IL-10. These molecules cause the inhibition or the
unresponsiveness of T-cell mediated responses.
factors. MSCs are able to inhibit the proliferation of CD8+
and CD4+ T lymphocytes and natural killer (NK) cells,
to suppress the immunoglobulin production by plasma
cells, to inhibit the maturation of dendritic cells (DCs)
and the proliferation of regulatory T cells [53]. It has
been demonstrated that MSCs are also able to inhibit T
lymphocyte pro-inﬂammatory cytokine production in vitro
[54, 55], as well as in vivo [56]. Their ability to modulate
the immune system opens a wide range of cell-mediated
applications, not only for autoimmune diseases and graft-
versus-host disease. Due to the particular immune system
dysregulation observed in ASDs [57, 58], mesenchymal stem
cell transplantation could oﬀer a unique tool to provide
better resolution for this disease. Indeed, in ASDs patho-
genesis, innate and adaptive immunity changes have been
reported [59]. ASD patients show an imbalance in CD3+,
CD4+, and CD8+ T cells, as well as in NK cells. In addition,
peripheralbloodmononuclearcells(PBMCs)extractedfrom
ASD patients are able to overproduce IL-1β resulting in
long-termimmunealterations[60].MSC-mediatedimmune
suppressive activity could restore this immune imbalance
(Figure 1). Indeed, MSC immunoregulatory eﬀects strongly
inhibitT-cellrecognitionandexpansionbyinhibitingTNF-α
and INF-γ production and increasing IL-10 levels [51].
It has been demonstrated that in postmortem brains
fromASDpatientsthereisevidenceofabnormalfunctioning
and cerebellum alterations [61–63]. Indeed, ASD subjects
show a decreased number of Purkinje cells in the cere-
bellum [64]. These changes could reﬂect defective cortical
organization in ASDs development. In addition, autism is
associated with dysregulation in the maturation and plas-
ticity of dendritic spine morphology [65]. Restoring injured
brain functioning could be achieved by stem-cell-based cell
replacement [66]. Indeed, transplanted MSCs are able to
promote synaptic plasticity and functional recovery and
rescue cerebellar Purkinje cells [67, 68]. Challenging newest
study from Deng et al. suggests that granulocyte colony-
stimulating factor (G-CSF) is able to mobilize MSCs into
peripheral blood. These mobilized MSCs are incorporated
and integrate into damaged brain in craniocerebral injured
mice, ameliorating the eﬀect of trauma [69]. It is noteworthy
that MSC ability to migrate to the sites of injury and
participate in the repair process is a key issue in tissue repair
[70]. Also by this way, MSC therapy could restore the altered
b r a i no r g a n i z a t i o ns e e ni na u t i s t i cs u b j e c t s( Table 1).
A key dilemma in stem-cell-based therapy for autism
treatmentiswhetherendogenousorexogenousMSCadmin-
istration is the best way of stem cell delivery. Endogenous4 Journal of Biomedicine and Biotechnology
Table 1: Potential ameliorative eﬀects mediated by MSCs in ASD
treatment.
ASD-induced changes in human
brain
Potential MSC ameliorative roles
seen in preclinical models
Abnormal functioning Improving functional recovery
Cerebellum alterations Integrating in altered brain and
restoring damaged functions
Decreased number of Purkinje
cells (PCs) Restoring cerebellar PCs
Defective cortical organization Reinforcing cortical plasticity
Altered plasticity of dendritic
spine morphology Promoting synaptic plasticity
strategy could be limited by the availability of MSCs.
Exogenous MSCs could show low rate of engraftment to
provide cellular replacement. It is unclear if diﬀerentiated
cells are able to develop functional interconnections with
the intrinsic cells of the recipient host [49]. Controversy,
few exogenous MSCs are able to exert paracrine activity.
Indeed, exogenously applied MSCs have been shown to
home to injured tissues and repair them by producing
chemokines, or by cell or nuclear fusion with host cells [71].
Ontheotherhand,exogenousculture-expandedMSCscould
address endogenous MSCs in order to activate them and
guide intrinsic repair [72]. In addition, exogenous delivery
bypasses surgical intervention on the autistic child.
Cellular therapy could represent a new frontier in the
treatment of several diseases. Despite the fact that MSCs
have been enrolled in several clinical trials, long-term safety
of MSC-based therapies is not yet well established; this fact
could be one major limitation to clinical translation [73].
At the present, there are no preclinical studies on the use
of MSCs in ASD models. There is just one clinical trial
(NCT01343511http://www.clinicaltrial.gov/)concerningthe
safety and eﬃcacy of human umbilical cord mesenchymal
stemcells(hUC-MSCs)andhumancordbloodmononuclear
cells(hCB-MNCs)transplantationinpatientswithautismby
Shenzhen Beike Bio-Technology Co., China. Results are not
yet posted.
However, personalized stem cell therapy will be the most
eﬀective treatment for a speciﬁc autistic child, opening a new
era in autism management in the next future.
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